Goldman Sachs analyst Robbie Marcus broke ranks with Wall Street this week, upgrading Intuitive Surgical to a buy rating while most of the Street maintains reduced targets on the Sunnyvale-based surgical robotics company. The stock has fallen 28% year-to-date through June 24, 2026, making it one of the worst-performing large-cap healthcare names even as the company continues to post revenue increases. The divergence between operating performance and market sentiment has created what Goldman characterizes as a valuation disconnect worth exploiting.
The sell-off stems from margin pressure and competitive anxiety rather than fundamental demand weakness. Intuitive reported first-quarter 2026 revenue growth of 12% year-over-year, driven by procedure volume increases across its installed base of da Vinci systems. But gross margins compressed 180 basis points as the company ramped production of its fifth-generation da Vinci 5 platform, which carries higher manufacturing costs during the scaling phase. Deutsche Bank analyst Pito Chickering cut his price target from $485 to $420 in May, citing near-term margin headwinds. Bank of America followed with a reduction to $395, pointing to elevated capital expenditure requirements for the da Vinci 5 rollout and lukewarm adoption signals from hospital systems facing their own budget constraints. Short interest in Intuitive has climbed to 3.2% of float, up from 1.8% at the start of the year.
Goldman's Marcus argues the market is overweighting transition costs and underweighting the durability of Intuitive's competitive moat. The firm's analysis of da Vinci utilization data shows procedure volumes per system grew 7% in the first quarter, indicating hospitals are expanding robotic surgery programs rather than pulling back. Instrumentation and accessory revenue, which carries higher margins than capital equipment sales, rose 14% in the quarter. Marcus projects gross margins will recover to historical levels by fourth-quarter 2026 as da Vinci 5 production scales and the company moves past initial yield curve inefficiencies. The analyst set a twelve-month price target of $525, implying 42% upside from current levels. Goldman's view assumes Intuitive places 350 to 375 da Vinci systems in 2026, broadly in line with management guidance, and sees minimal competitive displacement from emerging players like CMR Surgical or Medtronic's Hugo platform.
The bear case centers on saturation risk and the threat of genuine competition after two decades of near-monopoly positioning. Intuitive has installed more than 9,200 da Vinci systems worldwide, with penetration reaching 75% of U.S. hospitals performing soft-tissue surgery. Critics question how much runway remains for new system placements, particularly as hospital capital budgets tighten. CMR Surgical's Versius system has gained traction in Europe with a modular design that costs roughly 40% less than a da Vinci. Medtronic positioned Hugo as a cloud-connected alternative with data analytics capabilities Intuitive has been slower to develop. Johnson & Johnson's pending entry through its Ottava platform, expected to reach limited commercial release in late 2026, adds another credible competitor with established surgical relationships. The procedural robotics market is expanding, but Intuitive's share of that growth is no longer guaranteed. The company's operating margin peaked at 31% in 2024 and has since contracted to 27% as it invests in manufacturing capacity, R&D, and competitive responses.
What to Watch: Goldman's thesis depends on gross margin recovery materializing in fourth-quarter 2026 earnings, expected in January 2027. Track da Vinci 5 placement velocity when Intuitive reports second-quarter results in mid-July 2026. Watch for any revision to full-year system placement guidance, currently 1,350 to 1,450 units. CMR Surgical's planned U.S. regulatory submission for Versius, anticipated before September 2026, could force earlier price concessions than Goldman's model assumes.
